Novo Nordisk Unveils New Strength of Wegovy With Significant Weight Loss Results Novo Nordisk, a leading pharmaceutical company, has announced plans to seek approval from the UKs Medicines and Healthcare products Regulatory Agency (MHRA) for a new 7.2mg dose of its weight-loss drug Wegovy (semaglutide)
New England Journal of Medicine (2023) 3
Why It Is Not a Generic A generic drug is approved through an abbreviated pathway on a showing of bioequivalence to a specific reference product, and it carries FDA approval
It combines liposomal glutathione with fat-soluble vitamin C, liposomal NAD, resveratrol from Japanese knotweed extract, quercetin, alpha lipoic acid (ALA), astaxanthin, and green tea extract to create a well-rounded blend that complements glutathione at the center of the formula.
10(12):2985 [241 pp., see second to last paragraph for this quote]